Bio & Health Tech
OpenAI Acquires Orchestra Bio to Bridge the Gap Between Drug Discovery and Development
OpenAI has acquired Orchestra Bio, integrating its drug development coordination platform with OpenAI's Rosalind AI for life sciences. This move aims to accelerate drug discovery and development timelines by bridging scientific findings with operational execution.
Sofia Rodriguez·October 22, 2026
